Objective: This study assessed CLDN16 as a potential replacement or improvement biomarker for papillary thyroid cancer (PTC), addressing the limitations associated with the prevalently used BRAF-V600E mutation.
Design: Database analyses, tissue validation, RNA sequencing, and functional assays were conducted to evaluate CLDN16 as a PTC biomarker and its clinical application.
Methods: CLDN16 expression was examined in PTC and normal thyroid/para-tumor tissues and compared across various cancer types.